

Iain R Macpherson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9238328/publications.pdf>

Version: 2024-02-01

44
papers

2,028
citations

331259

21
h-index

288905

40
g-index

47
all docs

47
docs citations

47
times ranked

3826
citing authors

#	ARTICLE	IF	CITATIONS
1	Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	19
2	A randomised controlled trial of interventions for taxane-induced nail toxicity in women with early breast cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
3	Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i> -Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. <i>Cancer Discovery</i> , 2021, 11, 92-107.	7.7	36
4	Eribulin, Child-Pugh score, and liver-function tests: lessons from pivotal breast cancer studies 301 and 305. <i>Breast Cancer Research</i> , 2021, 23, 33.	2.2	3
5	Genomic profile of advanced breast cancer in circulating tumour DNA. <i>Nature Communications</i> , 2021, 12, 2423.	5.8	54
6	Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study. <i>Clinical Cancer Research</i> , 2021, 27, 5482-5491.	3.2	25
7	PINK1 drives production of mtDNA-containing extracellular vesicles to promote invasiveness. <i>Journal of Cell Biology</i> , 2021, 220, .	2.3	46
8	Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. <i>Lancet Oncology</i> , The, 2020, 21, 1296-1308.	5.1	196
9	Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution. <i>Lancet Oncology</i> , The, 2019, 20, e289.	5.1	6
10	The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation. <i>Journal of Clinical Epidemiology</i> , 2019, 106, 108-120.	2.4	49
11	Stochastic Pharmacokinetic-Pharmacodynamic Modeling for Assessing the Systemic Health Risk of Perfluorooctanoate (PFOA). <i>Toxicological Sciences</i> , 2018, 163, 293-306.	1.4	37
12	An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. <i>Journal of Clinical Epidemiology</i> , 2018, 99, 75-83.	2.4	25
13	Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels. <i>Nature Communications</i> , 2018, 9, 5069.	5.8	91
14	The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review. <i>Breast</i> , 2018, 42, 133-141.	0.9	4
15	A proteomic approach to identify endosomal cargoes controlling cancer invasiveness. <i>Journal of Cell Science</i> , 2017, 130, 697-711.	1.2	19
16	Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. <i>Nature Communications</i> , 2017, 8, 14206.	5.8	81
17	Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial. <i>Value in Health</i> , 2017, 20, 1311-1318.	0.1	31
18	Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice. <i>Clinical Oncology</i> , 2017, 29, 642-652.	0.6	85

#	ARTICLE	IF	CITATIONS
19	Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. <i>Nature Communications</i> , 2017, 8, 2255.	5.8	65
20	Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw050.	3.0	166
21	Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer. <i>Targeted Oncology</i> , 2016, 11, 579-591.	1.7	6
22	A randomised trial of the cool pad pillow topper versus standard care for sleep disturbance and hot flushes in women on endocrine therapy for breast cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 1821-1829.	1.0	9
23	Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. <i>Oncotarget</i> , 2016, 7, 13209-13220.	0.8	5
24	Practicalities of using an adaptive design for decision making within the optima trial: optimal personalized treatment of early breast cancer using multi-parameter tests. <i>Trials</i> , 2015, 16, .	0.7	0
25	Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. <i>European Journal of Cancer</i> , 2015, 51, 942-949.	1.3	47
26	Loading Dose Ibandronate Versus Standard Oral Ibandronate in Patients With Bone Metastases From Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 117-127.	1.1	5
27	Abstract P4-15-05: Effects on outcome of concomitant neoadjuvant chemotherapy-trastuzumab compared with sequential neoadjuvant chemotherapy followed by post-operative trastuzumab. , 2015, , .		0
28	CLIC3 controls recycling of late endosomal MT1-MMP and dictates invasion and metastasis in breast cancer. <i>Journal of Cell Science</i> , 2014, 127, 3893-901.	1.2	85
29	FAK Acts as a Suppressor of RTK-MAP Kinase Signalling in <i>Drosophila melanogaster</i> Epithelia and Human Cancer Cells. <i>PLoS Genetics</i> , 2014, 10, e1004262.	1.5	12
30	A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2014, 50, 3136-3144.	1.3	17
31	Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma. <i>European Journal of Cancer</i> , 2014, 50, 944-952.	1.3	27
32	Response to: "Letter to the editor, <i>European Journal of Cancer</i> "™, commenting on "Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma"™. <i>European Journal of Cancer</i> , 2014, 50, 2178-2179.	1.3	0
33	N-WASP coordinates the delivery and F-actin-mediated capture of MT1-MMP at invasive pseudopods. <i>Journal of Cell Biology</i> , 2012, 199, 527-544.	2.3	151
34	Rab25 and CLIC3 Collaborate to Promote Integrin Recycling from Late Endosomes/Lysosomes and Drive Cancer Progression. <i>Developmental Cell</i> , 2012, 22, 131-145.	3.1	275
35	Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. <i>BMC Cancer</i> , 2012, 12, 536.	1.1	7
36	Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane. <i>Breast Cancer: Targets and Therapy</i> , 2010, 2, 59.	1.0	1

#	ARTICLE	IF	CITATIONS
37	Abstract 3566: Anti-tumor activity of CXR1002, a novel anti-cancer compound that induces ER stress: Human tumor xenograft efficacy and in vitro mode of action. , 2010, , .		0
38	Recombinant human epoetin beta in the treatment of chemotherapy-related anemia. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 261.	0.9	5
39	Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. <i>Future Oncology</i> , 2009, 5, 421-432.	1.1	38
40	Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 6232-6240.	3.2	133
41	New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin. <i>Breast Cancer: Targets and Therapy</i> , 2009, 1, 1-18.	1.0	1
42	p120-catenin is required for the collective invasion of squamous cell carcinoma cells via a phosphorylation-independent mechanism. <i>Oncogene</i> , 2007, 26, 5214-5228.	2.6	51
43	Clinical Development of Src Family Kinase Inhibitors in Malignant Melanoma. <i>The Open Cancer Journal</i> , 2007, 1, 9-20.	0.2	1
44	Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 3014-3022.	1.9	110